Integra LifeSciences Holdings (IART) 2000年年度报告「NASDAQ」.pdf

1、2000 Annual ReportPresidents MessageTo Our Stockholders:Since I joined the Company just over three years ago,Integra has transformed itself from a small companyengaged primarily in the development of tissue regeneration products to a diversified medical technology compa-ny with a stable revenue base

2、 of commercially successful products.We now define ourselves as a leading,fully inte-grated player in the neurosurgical device market and a leader in the development and manufacturing of a broadrange of products based upon our proprietary technology for the regeneration of tissue in vivo.Total reven

3、ues grew67%in 2000 over the previous year.Today we speak of Integra in terms of its current profitability.In the third quarter of 2000,Integra reportedthe first operating profit in its history,a trend that continued into the fourth quarter excluding a non-recurringcharge.Additionally,we have substan

4、tially reduced our cash burn rate and expect that operating cash flows will bepositive in 2001.Integra NeuroSciences is a leading manufacturer and marketer of a broad range of implants,instruments,andsingle-use specialty medical products for use in neurosurgery,neurotrauma,and related critical care.

5、Our neuro-surgical devices include the DuraGenDural Graft Matrix for repair and regeneration of the dura mater,Caminoand Ventrixintracranial monitoring systems,Clinical Neuro Systemsdrainage systems,Heyer-Schulteshunt-ing products and the SelectorIntegra Ultrasonic Aspirator.Additionally,our launch

6、of the LICOXBrain Tissue Oxygen Monitoring System in the United States beganin the first quarter of 2001.The LICOXsystem provides for continuous quantitative regional monitoring of dis-solved oxygen and temperature in body fluids and tissues.The LICOXproduct gives Integra another leading andcompleme